Versant Capital Management
RNA icon

Versant Capital Management’s Atrium Therapeutics RNA Stock Holding History

Versant Capital Management’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.71K Buy
931
+666
+251% +$7.86K ﹤0.01% 2341
2026
Q2 		$3.56K Buy
+265
New +$3.46K ﹤0.01% 2496

Other funds holding RNA

Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Versant Capital Management's RNA Position: Q3 2026 in Review

Versant Capital Management increased its Atrium Therapeutics (RNA) stake by 251% in Q3 2026, buying an estimated $7.86K and bringing the position to 931 shares worth $7.71K. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

Versant Capital Management first reported a position in RNA in Q2 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Versant Capital Management held 931 shares of Atrium Therapeutics worth $7.71K as of Q3 2026.
  • Versant Capital Management bought 666 Atrium Therapeutics shares in Q3 2026, an estimated $7.86K.
  • Atrium Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2341 holding.
  • Versant Capital Management first reported a position in Atrium Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.